Combination treatment with monoclonal antibodies: Dupilumab and ustekinumab for the treatment of severe atopic dermatitis and Crohn disease
We report a case of dual biologic therapy with ustekinumab and dupilumab in a patient with severe Crohn disease and atopic dermatitis. There was no interference between these drugs after a 7-month follow-up.PMID:37929636 | DOI:10.1111/ajd.14185 (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - November 6, 2023 Category: Dermatology Authors: Alberto Alegre-Bailo Araceli S ánchez-Gilo In és Gonzalo González Francisco Javier Vicente Mart ín Source Type: research
Ustekinumab as induction and maintenance therapy for ulcerative colitis - national extended follow-up and a review of the literature
CONCLUSION: For moderate-to-severe UC in Australia, ustekinumab maintained efficacy beyond 3 years with a high persistence rate and no new safety signals.TRIAL REGISTRATION: The trial is registered at ANZCTR (identifier: ACTRN12622001332718).PMID:37909484 | DOI:10.1080/14740338.2023.2278686 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - November 1, 2023 Category: Drugs & Pharmacology Authors: J D Chetwood S Gupta K Subramaniam P De Cruz G Moore Y K An S J Connor M Kermeen S Paramsothy R W Leong Source Type: research
Comparative short-term risks of infection and serious infection in patients receiving biologic and small-molecule therapies for psoriasis and psoriatic arthritis: a systemic review and network meta-analysis of randomized controlled trials
CONCLUSION: This NMA provides a comprehensive assessment of the comparative short-term risks of infection, which could help physicians and patients to select individualized treatments for psoriasis.REGISTRATION: CRD42022359873.PMID:37901688 | PMC:PMC10612457 | DOI:10.1177/20406223231206225 (Source: Adv Data)
Source: Adv Data - October 30, 2023 Category: Epidemiology Authors: Hsien-Yi Chiu Yi-Teng Hung Yu-Huei Huang Source Type: research
Comparative short-term risks of infection and serious infection in patients receiving biologic and small-molecule therapies for psoriasis and psoriatic arthritis: a systemic review and network meta-analysis of randomized controlled trials
CONCLUSION: This NMA provides a comprehensive assessment of the comparative short-term risks of infection, which could help physicians and patients to select individualized treatments for psoriasis.REGISTRATION: CRD42022359873.PMID:37901688 | PMC:PMC10612457 | DOI:10.1177/20406223231206225 (Source: Adv Data)
Source: Adv Data - October 30, 2023 Category: Epidemiology Authors: Hsien-Yi Chiu Yi-Teng Hung Yu-Huei Huang Source Type: research
Bullous Wells Syndrome Induced by Ustekinumab
Ann Dermatol. 2023 May;35(Suppl 1):S180-S181. doi: 10.5021/ad.21.225.NO ABSTRACTPMID:37853906 | DOI:10.5021/ad.21.225 (Source: Annals of Dermatology)
Source: Annals of Dermatology - October 19, 2023 Category: Dermatology Authors: Yeona Kim Kyung-Nam Bae Jin-Hwa Son Kihyuk Shin Hoonsoo Kim Hyun-Chang Ko Byungsoo Kim Moon-Bum Kim Source Type: research
Bullous Wells Syndrome Induced by Ustekinumab
Ann Dermatol. 2023 May;35(Suppl 1):S180-S181. doi: 10.5021/ad.21.225.NO ABSTRACTPMID:37853906 | PMC:PMC10608391 | DOI:10.5021/ad.21.225 (Source: Annals of Dermatology)
Source: Annals of Dermatology - October 19, 2023 Category: Dermatology Authors: Yeona Kim Kyung-Nam Bae Jin-Hwa Son Kihyuk Shin Hoonsoo Kim Hyun-Chang Ko Byungsoo Kim Moon-Bum Kim Source Type: research
